An Open Label Feasibility Trial Investigating FE 202158 as Potential Primary Vasopressor Treatment in Patients With Vasodilatory Hypotension in Early Septic Shock.

Trial Profile

An Open Label Feasibility Trial Investigating FE 202158 as Potential Primary Vasopressor Treatment in Patients With Vasodilatory Hypotension in Early Septic Shock.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Selepressin (Primary)
  • Indications Hypotension; Septic shock
  • Focus Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 22 Apr 2014 New source identified and integrated; European Clinical Trials Database record.
    • 10 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top